Categories: NewsPharmaceutical

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.

HCW Conference Details:

Fireside Chat: Thursday, March 28, 2024, at 8:30 am ET
Speakers: David Domzalski, President and Chief Executive Officer
Iain Stuart, Ph.D., Chief Scientific Officer
Registration: Webcast Link
   

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain inhibitors, which comprise its InhiBET™ platform, include a locally administered pan-BD BET inhibitor (VYN201) and an orally available BD2-selective BET inhibitor (VYN202) that were licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

Staff

Recent Posts

Flower Expo Returns to Michigan and Illinois This Summer Following Blockbuster Northeast Event

Two-day cannabis trade events will connect brands, dispensaries, and budtenders for networking, product showcases, and…

15 hours ago

Sage Healthspan Launches AI-Powered, Privacy-First Wellness App to Bridge Critical Gaps in Preventative Healthcare

Orange County, California, June 27, 2025 (GLOBE NEWSWIRE) -- Sage Healthspan, a California-based digital health…

15 hours ago

theranos Calls on President Trump to Pardon Elizabeth Holmes

You Cannot Silence the SciencePALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- In less…

15 hours ago

Freeze Drying Equipment Market to Surge from USD 4.9 Billion to USD 8.4 Billion by 2032 – Meticulous Research®

Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across…

24 hours ago